Pharmaceutical Standardization of Vyaghrihareetaki Avaleha and Granules and their effect on Tamaka Shwasa (Bronchial Asthma)

Institute for Post Graduate Teaching and Research in Ayurveda0 个研究点目标入组 90 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients having signs and symptoms of Tamaka Shwasa as described in Ayurvedic classics.
•2. Mild persistent cases of Asthma (as per WHO GINA Guideline) of duration more than 6 months.
•3. Symptoms/exacerbation (Wheeze, cough and breathlessness) more than once a week but less than once a day in frequency

•1.Age more than 60 years and below 16 years.
•2.Mild intermittent, Moderated persistent, severe persistent to severe Asthma.
•3.Dyspnoea resulting from other diseases like left ventricular failure, COPD (Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc.
•4.Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions.
•5.Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded.
•6.HIV positive cases.
•7.Pregnant/lactating mother.
•8.Patients having classical symptoms of Maha, Urdha, Chinna and Kshudra Shwasa.

发起方

Institute for Post Graduate Teaching and Research in Ayurveda